INCYTE CORPORATION Cash and Cash Equivalents, Period Increase (Decrease)
INCYTE CORPORATION (INCY) reported Cash and Cash Equivalents, Period Increase (Decrease) of $247.17 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-15
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$228.54M, a 416.34% decline year-over-year.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $676.29M, a 631.56% increase year-over-year.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $89.93M.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$290.52M, a 313.34% decline year-over-year.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for fiscal 2017 was $247.17M, a 88.81% increase from fiscal 2016.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for fiscal 2016 was $130.90M, a 89.33% increase from fiscal 2015.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for fiscal 2015 was $69.14M.
- INCYTE CORPORATION cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$19.13M, a 107.73% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$228.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $447.75M derived: sum of 2 quarters · filed 2018-02-15 | $537.69M derived: sum of 3 quarters · filed 2018-02-15 | $247.17M 10-K · filed 2018-02-15 |
| 2017-09-30 | $676.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $766.22M derived: sum of 2 quarters · filed 2017-10-31 | $475.70M 10-Q · filed 2017-10-31 | $547.95M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | $89.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$200.59M 10-Q · filed 2017-08-01 | -$128.34M derived: sum of 3 quarters · filed 2018-02-15 | -$35.90M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | -$290.52M 10-Q · filed 2017-05-04 | -$218.28M derived: sum of 2 quarters · filed 2018-02-15 | -$125.83M derived: sum of 3 quarters · filed 2018-02-15 | -$295.79M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $72.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $164.69M derived: sum of 2 quarters · filed 2018-02-15 | -$5.27M derived: sum of 3 quarters · filed 2018-02-15 | $130.90M 10-K · filed 2018-02-15 |
| 2016-09-30 | $92.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$77.52M derived: sum of 2 quarters · filed 2017-10-31 | $58.66M 10-Q · filed 2017-10-31 | $134.30M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$169.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$33.78M 10-Q · filed 2017-08-01 | $41.85M derived: sum of 3 quarters · filed 2018-02-15 | $47.97M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $136.18M 10-Q · filed 2017-05-04 | $211.81M derived: sum of 2 quarters · filed 2018-02-15 | $217.93M derived: sum of 3 quarters · filed 2018-02-15 | $235.79M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $75.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $81.76M derived: sum of 2 quarters · filed 2018-02-15 | $99.62M derived: sum of 3 quarters · filed 2018-02-15 | $69.14M 10-K · filed 2018-02-15 |
| 2015-09-30 | $6.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $23.98M derived: sum of 2 quarters · filed 2016-11-01 | -$6.50M 10-Q · filed 2016-11-01 | $63.80M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $17.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$12.62M 10-Q · filed 2016-08-09 | $57.68M derived: sum of 3 quarters · filed 2017-02-14 | $33.42M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | -$30.48M 10-Q · filed 2016-05-09 | $39.82M derived: sum of 2 quarters · filed 2017-02-14 | $15.56M derived: sum of 3 quarters · filed 2017-02-14 | |
| 2014-12-31 | $70.29M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $46.03M derived: sum of 2 quarters · filed 2017-02-14 | -$19.13M 10-K · filed 2017-02-14 | |
| 2014-09-30 | -$24.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$89.42M 10-Q · filed 2015-11-03 | ||
| 2014-06-30 | -$65.17M 10-Q · filed 2015-08-04 | |||
| 2013-12-31 | $247.37M 10-K · filed 2016-02-12 | |||
| 2011-09-30 | -$46.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$65.52M derived: sum of 2 quarters · filed 2011-10-27 | -$105.58M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | -$18.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$58.84M 10-Q · filed 2011-07-28 | ||
| 2011-03-31 | -$40.07M 10-Q · filed 2011-05-03 | |||
| 2010-09-30 | -$25.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$15.94M derived: sum of 2 quarters · filed 2011-10-27 | -$61.02M 10-Q · filed 2011-10-27 | |
| 2010-06-30 | $9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$35.74M 10-Q · filed 2011-07-28 | ||
| 2010-03-31 | -$45.08M 10-Q · filed 2011-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |